Lazard上市基礎設施主動型ETF GLIX 深 滬
等待開盤 08-22 09:30:00 美东时间
27.14
-0.250
-0.91%
華盛通- 最 高27.355
- 今 開27.32
- 成交量 4255股
- 最 低 27.14
- 昨 收 27.39
- 總市值 4749.01万
- 52周最高 30.47
- 市盈率 靜 --
- 換手率 0.24%
- 52周最低 24.7399
- 委 比 -50.00%
- 總股本 174.98万
- 歷史最高 30.47
- 量 比 0.63
- 振 幅 0.78%
- 歷史最低 24.7399
- 每 手 1
- 風險率 1.11%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BioLineRx Announces New Preclinical Data That Further Support The Recently Initiated Phase 1/2a Clinical Trial Evaluating GLIX1 For Recurrent And Progressive GBM And Other High-Grade Gliomas
GBM remains one of the most aggressive and treatment-resistant cancers, urgently in need of breakthrough innovations and more effective treatment.In a comprehensive pre-clinical program, orally administered GLIX1
05-19 19:04
BioLineRx Announces That The First Patient Has Been Dosed In Its Phase 1/2A Study Of GLIX-1 For The Treatment Of Recurrent And Progressive Glioblastoma And Other High-Grade Gliomas
The GLIX1 program is being conducted under a collaboration between BioLineRx and Hemispherian announced in September 2025. The patient was dosed at NYU Langone Health under the supervision of Dr. Alexandra Miller, Chief
04-28 19:13
BioLineRx Launches First-in-Human Trial of GLIX1 for Glioblastoma
An update from Bioline RX Ltd Sponsored ADR ( ($BLRX) ) is now available. BioLi...
03-26 19:28
BioLineRx Launches First Human Trial For Brain Cancer Drug
BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced the initiation of a first-in-human, Phase
03-26 19:17
